WO2025252100 - LIGAND-DRUG CONJUGATE HAVING FREE PAYLOAD RECOVERY UNIT
National phase entry is expected:
Publication Number
WO/2025/252100
Publication Date
11.12.2025
International Application No.
PCT/CN2025/098941
International Filing Date
04.06.2025
Title **
[English]
LIGAND-DRUG CONJUGATE HAVING FREE PAYLOAD RECOVERY UNIT
[French]
CONJUGUÉ LIGAND-MÉDICAMENT AYANT UNE UNITÉ DE RÉCUPÉRATION DE CHARGE UTILE LIBRE
[Chinese]
一种自带游离载荷回收单元的配体药物偶联物
Applicants **
REMEGEN CO., LTD.
Inventors
FANG, Jianmin
WANG, Lili
JIANG, Jing
LI, Dong
ZHANG, Wei
LI, Yuanhao
WANG, Zhulun
MIN, Xiaoshan
WANG, Ling
XIN, Yinghao
HE, Chenglin
XU, Menglong
Priority Data
202410722924.6
05.06.2024
CN
202410729765.2
06.06.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4131 | |
| EPO | Filing, Examination, Granting | 65933 | |
| Japan | Filing, Examination, Granting | 4069 | |
| South Korea | Filing, Examination, Granting | 6291 | |
| USA | Filing, Examination, Granting | 16590 |
Total:
97,014
Contact Us
Abstract[English]
A ligand-drug conjugate having a free payload recovery unit, and a use thereof in preventing or treating diseases. The ligand-drug conjugate can remove a free payload by means of a connected recovery unit capable of binding to the free payload, significantly improving the safety of medication. Moreover, by means of recovering the free payload, the payload carried by the ligand-drug conjugate as a whole can be increased, thereby compensating for activity loss caused by payload shedding. Therefore, by means of introducing the recovery unit, free payload is recovered, which can significantly increase the safety and effectiveness of the ligand-drug conjugate, and expand a treatment window.[French]
L'invention concerne un conjugué ligand-médicament ayant une unité de récupération de charge utile libre, et son utilisation dans la prévention ou le traitement de maladies. Le conjugué ligand-médicament peut éliminer une charge utile libre au moyen d'une unité de récupération connectée capable de se lier à la charge utile libre, améliorant sensiblement la sécurité du médicament. De plus, en récupérant la charge utile libre, la charge utile transportée par le conjugué ligand-médicament dans son ensemble peut être augmentée, ce qui permet de compenser la perte d'activité provoquée par le déversement de la charge utile. L'introduction de l'unité de récupération a ainsi pour effet de récupérer la charge utile libre, ce qui peut augmenter sensiblement la sécurité et l'efficacité du conjugué ligand-médicament, et étendre une fenêtre de traitement.[Chinese]
一种自带游离载荷回收单元的配体药物偶联物及其在预防或治疗疾病中的应用，该配体药物偶联物通过连接的可结合游离载荷的回收单元，可以清除游离的载荷，显著地提升了用药安全性，同时通过回收游离载荷又可以整体上增加配体药物偶联物所携带的载荷，弥补因载荷脱落而导致的活性损失。因此通过引入回收单元，实现对游离载荷的回收，可以显著增加配体偶联药物的安全性和有效性，并扩大治疗窗。